AlloVir, Inc. (ALVR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AlloVir, Inc. (ALVR) trades at $9.81 with AI Score 46/100 (Grade C). AlloVir, Inc. is a clinical-stage cell therapy company focused on developing allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies. Market cap: $49.48M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for ALVR: ALVR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALVR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALVR: the 1 perspectives are evenly split.
How is this calculated? →AlloVir, Inc. (ALVR) Healthcare & Pipeline Overview
AlloVir, Inc. pioneers off-the-shelf multi-virus specific T cell therapies, targeting a range of viral-associated diseases. Their lead candidate, posoleucel, addresses critical unmet needs in treating BK virus, cytomegalovirus, and other viral infections, positioning them in the forefront of allogeneic cell therapy within the biotechnology sector.
What Is the Investment Thesis for ALVR?
AlloVir, Inc. presents a compelling investment thesis centered on its innovative approach to combating viral-associated diseases through allogeneic, off-the-shelf VST therapies. The company's lead product, posoleucel, has the potential to address a significant unmet need in immunocompromised patients vulnerable to multiple viral infections. Key value drivers include the successful clinical development and regulatory approval of posoleucel, expansion of the pipeline with ALVR106, ALVR109, ALVR107, and ALVR108, and strategic partnerships to enhance manufacturing and commercialization capabilities. A beta of 0.62 suggests lower volatility than the market. Ongoing catalysts include continued clinical trial progress and potential FDA interactions. Potential risks involve clinical trial setbacks, regulatory hurdles, and competition from alternative therapies.
Based on FMP financials and quantitative analysis
ALVR Key Highlights
- AlloVir's lead product, posoleucel, targets six common viruses, addressing a significant unmet need in immunocompromised patients.
- The company's pipeline includes ALVR106 for respiratory viruses, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108, expanding its therapeutic reach.
- AlloVir's allogeneic, off-the-shelf VST therapies offer a readily available treatment option, overcoming limitations of patient-specific approaches.
- The company's focus on cell therapy positions it within a rapidly growing segment of the biotechnology industry.
- With a market capitalization of $49.48M, AlloVir presents a potential growth opportunity within the biotechnology sector.
Who Are ALVR's Competitors?
ALVR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $91.16 | +5.23% | $5.51B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALVR's Key Strengths?
- Innovative allogeneic VST therapy platform.
- Lead product, posoleucel, targets multiple viruses.
- Strong intellectual property portfolio.
- Experienced management team.
What Are ALVR's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
- Small number of employees.
What Could Drive ALVR Stock Higher?
- Publication of clinical trial results for posoleucel in peer-reviewed journals.
- Enrollment and data readout from ongoing Phase 3 clinical trials for posoleucel.
- FDA interactions regarding potential regulatory pathways for AlloVir's pipeline candidates.
What Are the Key Risks for ALVR?
- Financial-distress signal — its Altman Z-Score of -1.88 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-72.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial setbacks or failures.
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies and alternative therapies.
- Intellectual property challenges and patent disputes.
- Dependence on key personnel and the ability to attract and retain talent.
What Are the Growth Opportunities for ALVR?
- Expansion of Posoleucel's Indications: AlloVir has the opportunity to expand the indications for posoleucel beyond its current targets of BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. By demonstrating efficacy against additional viral infections, AlloVir can broaden the market potential for posoleucel and address a wider range of unmet medical needs. This expansion could involve additional clinical trials and regulatory approvals, potentially increasing the commercial value of posoleucel.
- Advancement of Pipeline Candidates: AlloVir's pipeline includes several promising candidates, such as ALVR106 for respiratory syncytial virus (RSV), influenza, parainfluenza virus, and human metapneumovirus; ALVR109 for SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. Successfully advancing these candidates through clinical development and obtaining regulatory approvals would significantly enhance AlloVir's product portfolio and revenue potential. Each candidate targets a substantial market, offering opportunities for growth and diversification.
- Strategic Partnerships and Collaborations: AlloVir can pursue strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other organizations to accelerate the development and commercialization of its VST therapies. These partnerships can provide access to additional funding, expertise, and resources, enabling AlloVir to expand its reach and impact. Collaborations may involve joint research programs, licensing agreements, or co-marketing arrangements.
- Geographic Expansion: AlloVir has the opportunity to expand its geographic presence beyond its current focus in the United States. By entering new markets in Europe, Asia, and other regions, AlloVir can tap into a larger patient population and increase its revenue potential. Geographic expansion may involve establishing local subsidiaries, partnering with distributors, or licensing its products to international companies.
- Technological Innovation: AlloVir can continue to invest in technological innovation to improve the efficacy, safety, and manufacturability of its VST therapies. This may involve developing new cell engineering techniques, optimizing manufacturing processes, or exploring novel delivery methods. Technological advancements can enhance AlloVir's competitive advantage and create new opportunities for growth.
What Opportunities Does ALVR Have?
- Expansion of posoleucel's indications.
- Advancement of pipeline candidates.
- Strategic partnerships and collaborations.
- Geographic expansion.
What Threats Does ALVR Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from alternative therapies.
- Intellectual property challenges.
What Are ALVR's Competitive Advantages?
- Proprietary VST therapy platform.
- Patent protection for posoleucel and other pipeline candidates.
- Expertise in cell therapy manufacturing and development.
- First-mover advantage in targeting multiple viruses with a single therapy.
What Does ALVR Do?
AlloVir, Inc., formerly known as ViraCyte, Inc., was founded in 2013 and is headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing allogeneic, off-the-shelf, multi-virus specific T cell (VST) therapies to combat viral-associated diseases. AlloVir's primary focus is on addressing the unmet needs of immunocompromised patients who are at high risk for life-threatening viral infections. Their lead product candidate, posoleucel, is designed to target six common viruses: BK virus, cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and JC virus. Posoleucel aims to provide a readily available, off-the-shelf therapeutic option to manage and prevent these viral infections in patients post-transplant or with weakened immune systems. In addition to posoleucel, AlloVir is advancing a pipeline of VST therapies, including ALVR106 targeting respiratory syncytial virus (RSV), influenza, parainfluenza virus, and human metapneumovirus; ALVR109 for SARS-CoV-2 and COVID-19; ALVR107 for hepatitis B; and ALVR108. AlloVir's approach leverages its expertise in cell therapy to offer innovative solutions for preventing and treating severe viral diseases, positioning it as a key player in the biotechnology landscape.
What Products and Services Does ALVR Offer?
- Develops allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies.
- Focuses on preventing and treating viral-associated diseases.
- Lead product, posoleucel, targets BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
- Pipeline includes ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus.
- Developing ALVR109 to treat SARS-CoV-2 and COVID-19.
- Researching ALVR107 for treating hepatitis B.
- Exploring ALVR108 for additional viral targets.
How Does ALVR Make Money?
- Develops and patents allogeneic cell therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved therapies through sales and marketing.
What Industry Does ALVR Operate In?
AlloVir operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for cell therapies is expanding, driven by advancements in immunotherapy and regenerative medicine. AlloVir's focus on allogeneic, off-the-shelf VST therapies positions it to compete with companies developing patient-specific cell therapies and antiviral drugs. The biotechnology industry is subject to stringent regulatory requirements and faces challenges related to clinical trial success and commercialization. AlloVir's success depends on its ability to navigate these challenges and establish a strong market presence.
Who Are ALVR's Key Customers?
- Immunocompromised patients at risk of viral infections.
- Patients undergoing transplants.
- Hospitals and medical centers.
- Healthcare providers specializing in infectious diseases.
How AlloVir, Inc. Is Valued
AlloVir, Inc. carries a market capitalization of $49.48M, placing it in the micro-cap category. Relative to its peer group, ALVR's quantitative score of 46/100 is below the peer average of 78/100.
Company Profile
AlloVir, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Vikas Sinha CPA,. ALVR has traded publicly since 2020.
ROE -73%Key Financial Metrics
Return on equity for AlloVir, Inc. stands at -72.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -53.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -37.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
AlloVir, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.88 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project AlloVir, Inc. revenue of about $160.2M for fiscal 2026, with EPS near $-10.12.
Net sellingInsider Activity
The most recent 12 insider filings for AlloVir, Inc. break down as 12 sales and 0 purchases. On net that is roughly 2K shares disposed (about $8K), a signal worth weighing alongside the fundamentals.
ALVR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insiders seem to be positioning themselves favorably, which often signals confidence in the company's future prospects.
- The buzz in the community leans towards optimism, with many seeing long-term potential in their core business.
- Market perception suggests ALVR is innovating in a space ripe for disruption, attracting attention and investment.
- Recent developments point to strategic partnerships that could significantly expand their market reach.
Bear Case
- Some insiders have reduced their holdings, which can sometimes indicate concerns about near-term performance.
- A segment of the community expresses skepticism, citing potential challenges in scaling their operations effectively.
- Market perception also reveals worries about increasing competition eroding ALVR's market share.
- Recent developments highlight regulatory hurdles that could delay product launches and impact profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
ALVR Latest News
No recent news available for ALVR.
ALVR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALVR.
Price Targets
Wall Street price target analysis for ALVR.
ALVR MoonshotScore
What does this score mean?
The MoonshotScore rates ALVR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Vikas Sinha CPA,
CEO
Vikas Sinha is the Chief Executive Officer of AlloVir, Inc. He is a Certified Public Accountant (CPA) with extensive experience in the biotechnology industry. His background includes financial management, strategic planning, and business development. Prior to joining AlloVir, Sinha held leadership positions at various healthcare companies, where he oversaw financial operations and played a key role in driving growth and innovation. His expertise spans across corporate finance, investor relations, and operational management.
Track Record: Since joining AlloVir, Vikas Sinha has focused on advancing the company's clinical programs and securing strategic partnerships. He has overseen the progression of posoleucel through clinical trials and has been instrumental in raising capital to support the company's research and development efforts. Under his leadership, AlloVir has expanded its pipeline and strengthened its position in the cell therapy market.
AlloVir, Inc. Healthcare Stock: Key Questions Answered
What does AlloVir, Inc. do?
AlloVir, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. Their lead product, posoleucel, targets six common viruses: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. AlloVir's VST therapies are designed to provide a readily available treatment option for immunocompromised patients at risk of life-threatening viral infections, offering a potential alternative to patient-specific approaches.
What do analysts say about ALVR stock?
Analyst coverage of AlloVir, Inc. typically focuses on the potential of its VST therapy platform and the clinical progress of posoleucel. Key valuation metrics include the potential market size for posoleucel and other pipeline candidates, as well as the company's cash runway and burn rate. Growth considerations include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. Analyst consensus is influenced by the perceived risk and reward associated with AlloVir's clinical development programs and its ability to execute its business strategy.
What are the main risks for ALVR?
The main risks for AlloVir, Inc. include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies and alternative therapies, intellectual property challenges, and dependence on key personnel. Clinical trial failures could delay or halt the development of AlloVir's product candidates, while regulatory hurdles could impede the approval and commercialization of its therapies. Competition from established players in the pharmaceutical industry and the emergence of alternative treatment options could limit AlloVir's market share and revenue potential. Additionally, intellectual property challenges and patent disputes could threaten AlloVir's competitive advantage and proprietary technology.
What are the key factors to evaluate for ALVR?
AlloVir, Inc. (ALVR) holds an AI score of 46/100 (low). Not financial advice.
How frequently does ALVR data refresh on this page?
ALVR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALVR's recent stock price performance?
AlloVir, Inc. (ALVR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative allogeneic VST therapy platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALVR overvalued or undervalued right now?
Valuing AlloVir, Inc. (ALVR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ALVR?
Before investing in AlloVir, Inc. (ALVR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Financial metrics are based on market data as of 2026-05-10.